Is AI Drug Discovery Actually Working? What the 2026 Clinical Trial Data Shows
Dr. Dereck Mush, MD, MBA
What they do
PostEra offers Manifold, an AI-powered platform that designs and optimizes synthesis routes for novel chemical compounds. Pharmaceutical companies and medicinal chemists use the software to evaluate compound synthesizability and accelerate the design-make-test-analyze cycle of small molecule drug discovery.
The record
- Vertical
- Pharma & Drug Discovery
- Sub-segment
- AI drug discovery
- Product type
- Platform software
- Stage
- Series A
- Headquarters
- Boston, USA
- Region
- North America
- Founded
- 2019
- Total funding
- $26M raised
Notable investors: Bessemer Venture Partners, Playground Global, Outset Capital, Y Combinator.
Also in Pharma & Drug Discovery
Related on The Signal
Dr. Dereck Mush, MD, MBA
What Pharma Is Buying From AI Drug Discovery: Inside AstraZeneca’s insitro Deal
Dr. Dereck Mush, MD, MBAThe HealthTech Signal
Chai Discovery triples its valuation as pharma buys into AI-designed molecules
Chai Discovery triples its valuation as pharma buys into AI-designed molecules
Dr. Dereck Mush, MD, MBA
AI is moving upstream, from molecule design into disease target identification itself
Dr. Dereck Mush, MD, MBA